openPR Logo
Press release

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, Trends, and Forecast Report 2017

07-07-2017 01:52 PM CET | Health & Medicine

Press release from: Business Insights Report - MRH

Business Insights Report

Business Insights Report

Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017” to its report offerings. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Request Free Sample Report: www.marketresearchhub.com/enquiry.php?type=S&repid=1217012

Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017, provides an overview of the Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline landscape.

Opioid-induced bowel dysfunction (OIBD) is refers to a collection of primarily gastrointestinal motility disorders induced by opioids. OIBD is commonly associated with the chronic use of opioid analgesics. Symptoms include constipation, anorexia, nausea and vomiting, gastro-esophageal reflux, delayed digestion, abdominal pain, flatulence, bloating, hard stool, straining during bowel movement and incomplete evacuation. Treatment includes laxatives, stool softeners, osmotic agents and opioid antagonist.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 3 and 3 respectively.

Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Read Full Report with TOC: www.marketresearchhub.com/report/opioid-induced-bowel-dys...

Table of Contents:
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Overview
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Companies Involved in Therapeutics Development
ChironWells GmbH
RaQualia Pharma Inc
Vitality Biopharma Inc
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Drug Profiles
ORP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORP-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00433412 - Drug Profile
Product Description
Mechanism Of Action

About Market Research Hub:
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:
90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: www.marketresearchhub.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, Trends, and Forecast Report 2017 here

News-ID: 613093 • Views: 105

More Releases from Business Insights Report - MRH

Global Outdoor Cabinet Heat Exchange Equipments Market Research and Forecast Rep …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Global Outdoor Cabinet Heat Exchange Equipments Market Research Report 2017” to its report offerings. The report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Outdoor Cabinet Heat Exchange Equipments in these regions, from 2012 to 2022 (forecast). Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1220159 The global Outdoor Cabinet Heat Exchange
Global Nichrome Film Resistor Market - Industry Analysis, Growth, Trends, and Fo …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Global Nichrome Film Resistor Market Research Report 2017” to its report offerings. The report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Nichrome Film Resistor in these regions, from 2012 to 2022 (forecast). Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1220152 The global Nichrome Film Resistor market is valued at USD
Global Embolization Devices Market - Industry Analysis, Growth, Trends, and Fore …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Global Embolization Devices Market Research Report 2017” to its report offerings. The report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Embolization Devices in these regions, from 2012 to 2022 (forecast). Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1217154 The global Embolization Devices market is valued at USD XX million in
Global Duck Meats Industry Analysis, Size, Share, Growth, Trends, and Forecast R …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Global Duck Meats Market Research Report 2017” to its report offerings. The report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Duck Meats in these regions, from 2012 to 2022 (forecast). Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1217153 The report is segmented into several key Regions, with production, consumption, revenue

All 5 Releases


More Releases for OIBD

Global Therapeutic Landscape Of Opioid-Induced Bowel Dysfunction (OBD) Industry …
Overview Opioid-induced bowel dysfunction (OIBD) is refers to a collection of primarily gastrointestinal motility disorders induced by opioids. OIBD is commonly associated with the chronic use of opioid analgesics. Symptoms include constipation, anorexia, nausea and vomiting, gastro-esophageal reflux, delayed digestion, abdominal pain, flatulence, bloating, hard stool, straining during bowel movement and incomplete evacuation. Treatment includes laxatives, stool softeners, osmotic agents and opioid antagonist.  Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555349-opioid-induced-bowel-dysfunction-obd-or-oibd-pipeline-review-h1-2017 Report Highlights   The Pharmaceutical and
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Gh …
"The Report Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is
Latest article on Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Revi …
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Bowel Dysfunction Pipeline Review, H2 2016, provides an overview of the Opioid-Induced Bowel Dysfunction (Toxicology) pipeline landscape. Opioid-induced bowel dysfunction (OIBD) is refers to a collection of primarily gastrointestinal motility disorders induced by opioids. OIBD is commonly associated with the chronic use of opioid analgesics. Symptoms include constipation, anorexia, nausea and vomiting, gastro-oesophageal reflux, delayed digestion, abdominal pain, flatulence, bloating,